International Journal of Endocrinology and Metabolism

Published by: Kowsar

Acromegaly With Cardiomyopathy, Cardiac Thrombus and Hemorrhagic Cerebral Infarct: A Case Report of Therapeutic Dilemma With Review of Literature

Erick Mendoza 1 , * , Chandy Lou Malong 1 , Mary Jane Tanchee-Ngo 1 and Leilani Mercado-Asis 1
Authors Information
1 Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Manila, Philippines
Article information
  • International Journal of Endocrinology and Metabolism: April 01, 2015, 13 (2); e18841
  • Published Online: April 30, 2015
  • Article Type: Case Report
  • Received: March 9, 2014
  • Revised: May 19, 2014
  • Accepted: May 31, 2014
  • DOI: 10.5812/ijem.18841

To Cite: Mendoza E, Malong C L, Tanchee-Ngo M J, Mercado-Asis L. Acromegaly With Cardiomyopathy, Cardiac Thrombus and Hemorrhagic Cerebral Infarct: A Case Report of Therapeutic Dilemma With Review of Literature, Int J Endocrinol Metab. 2015 ; 13(2):e18841. doi: 10.5812/ijem.18841.

Copyright © 2015, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
  • 1. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab. 2006; 91(1): 121-8[DOI][PubMed]
  • 2. Bihan H, Espinosa C, Valdes-Socin H, Salenave S, Young J, Levasseur S, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab. 2004; 89(11): 5308-13[DOI][PubMed]
  • 3. Lopez-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moya-Mur JL, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab. 1997; 82(4): 1047-53[DOI][PubMed]
  • 4. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol. 2005; 153(6): 737-40[DOI][PubMed]
  • 5. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013; 16(3): 294-302[PubMed]
  • 6. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009; 94(5): 1509-17[DOI][PubMed]
  • 7. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab. 1999; 84(1): 17-23[DOI][PubMed]
  • 8. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab. 2008; 93(7): 2639-46[DOI][PubMed]
  • 9. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007; 92(5): 1743-7[DOI][PubMed]
  • 10. Colao A, Marek J, Goth MI, Caron P, Kuhn JM, Minuto FM, et al. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab. 2008; 93(6): 2243-8[DOI][PubMed]
  • 11. Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, et al. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab. 2009; 94(4): 1255-63[DOI][PubMed]
  • 12. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011; 96(5): 1327-35[DOI][PubMed]
  • 13. Moyes VJ, Metcalfe KA, Drake WM. Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur J Endocrinol. 2008; 159(5): 541-5[DOI][PubMed]
  • 14. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab. 2007; 92(2): 476-82[DOI][PubMed]
  • 15. Bianchi A, Valentini F, Iuorio R, Poggi M, Baldelli R, Passeri M, et al. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res. 2013; 32: 40[DOI][PubMed]
  • 16. Frohman LA, Bonert V. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary. 2007; 10(3): 283-9[PubMed]
  • 17. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004; 89(4): 1613-7[DOI][PubMed]
  • 18. Brada M, Burchell L, Ashley S, Traish D. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys. 1999; 45(3): 693-8[PubMed]
  • 19. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab. 2000; 85(11): 4099-103[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments